Diamant Asset Management Inc. Boosts Stock Holdings in Eli Lilly and Company $LLY

Diamant Asset Management Inc. lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 119,923.8% in the 1st quarter, Holdings Channel.com reports. The fund owned 1,070,612 shares of the company’s stock after buying an additional 1,069,720 shares during the quarter. Diamant Asset Management Inc.’s holdings in Eli Lilly and Company were worth $107,061,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. MRA Advisory Group lifted its position in Eli Lilly and Company by 4.6% in the 1st quarter. MRA Advisory Group now owns 1,031 shares of the company’s stock valued at $949,000 after acquiring an additional 45 shares in the last quarter. Caldwell Trust Co boosted its stake in Eli Lilly and Company by 2.1% during the 1st quarter. Caldwell Trust Co now owns 21,732 shares of the company’s stock valued at $19,988,000 after purchasing an additional 437 shares during the last quarter. AGH Wealth Advisors LLC increased its holdings in shares of Eli Lilly and Company by 3.8% in the 1st quarter. AGH Wealth Advisors LLC now owns 846 shares of the company’s stock worth $778,000 after purchasing an additional 31 shares in the last quarter. Onyx Bridge Wealth Group LLC raised its stake in shares of Eli Lilly and Company by 2.6% in the first quarter. Onyx Bridge Wealth Group LLC now owns 1,523 shares of the company’s stock worth $1,401,000 after purchasing an additional 39 shares during the last quarter. Finally, Trilogy Capital Inc. raised its stake in shares of Eli Lilly and Company by 8.7% in the first quarter. Trilogy Capital Inc. now owns 5,436 shares of the company’s stock worth $5,000,000 after purchasing an additional 434 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on LLY shares. Guggenheim reaffirmed a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Wall Street Zen upgraded Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Weiss Ratings lowered Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, May 19th. Rothschild & Co Redburn upped their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Finally, Bank of America raised their price target on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,235.07.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The FDA selected Eli Lilly for its new PreCheck pilot program, which is designed to speed review of new U.S. manufacturing facilities. That matters because Lilly is spending $27 billion to build four plants, so faster approvals could support capacity expansion and future drug supply. Article Title
• Positive Sentiment: Lilly’s Jaypirca received a positive opinion from Europe’s CHMP for chronic lymphocytic leukemia, improving the odds of broader European approval and potentially expanding the drug’s commercial opportunity. Article Title
• Positive Sentiment: The stock hit a new all-time high and 52-week high as investors reacted to recent pipeline progress, including positive Jaypirca data and expanded Medicare access for Zepbound and other obesity treatments, which boosts the outlook for Lilly’s growth franchises. Article Title

Eli Lilly and Company Stock Up 1.5%

NYSE LLY opened at $1,226.22 on Tuesday. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,238.00. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $1.15 trillion, a P/E ratio of 43.56, a price-to-earnings-growth ratio of 1.32 and a beta of 0.53. The stock’s 50-day moving average price is $1,042.73 and its 200-day moving average price is $1,022.85.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s revenue was up 55.5% on a year-over-year basis. During the same period in the previous year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.